LNP-023

Inhibitor of CFB

Structure

Information

Protein target names: CFB

Mechanism of action: Inhibitor

Recommended in-cell concentration:
up to 1 uM

In Vitro Validations

Uniprot ID: P00751
Target Class: Other
Target SubClass: Serine Protease
Potency: Kd
Potency Value: 7.9 nM
Potency Assay: SPR
PDB ID for probe-target interaction (3D structure): 6RAV
Structure-activity relationship: yes, check DOI: 10.1021/acs.jmedchem.9b01870
Target aliases:
Complement factor B, BFD, BF, CFB, CFAB_HUMAN, GBG ...

DOI Reference: 10.1073/pnas.1820892116

Uniprot ID: P00751
Target Class: Other
Target SubClass: Serine Protease
Potency: IC50
Potency Value: 12 nM
Potency Assay: Half-maximal inhibition of human FB in TR-FRET based competition binding assay (FB-comp)
PDB ID for probe-target interaction (3D structure): --
Target aliases:
Complement factor B, BFD, BF, CFB, CFAB_HUMAN, GBG ...

DOI Reference: 10.1073/pnas.1820892116

In Cell Validations

In Vivo Data

I have extra information to add

SERP ratings and comments


SERP Ratings

In Cell Rating
In Model Organisms

SERP Comments:

LNP023 is a first in class, potent reversible inhibitor of the serine protease factor B (FB). This protease is a key component of the alternative complement pathway. This pathway is dysregulated in a number of diseases, and a number of targets in the pathway are active subjects of drug discovery programs. The compound was optimized using structure-based drug design and a number of useful crystal structures have been deposited. LPN023 has IC50 values >30 micromolar for 41 other proteases tested. The selectivity is likely due to unique features of the FB active site. It also is inactive (IC50>30 micromolar) across a panel of 110 enzymes, receptors, and ion channels. It exhibits the expected on-target pharmacology and in vivo activity. Phase 1 trials have been completed and it is in phase 2 trials for several diseases.

(last updated: 12 Mar 2021 )